Who is sponsoring PARADOR?

PARADOR is sponsored by Brigham and Women's Hospital.

What condition does PARADOR study?

PARADOR studies Heart Failure With Reduced Ejection Fraction.

What drugs are being tested in PARADOR?

Interventions: sacubitril/valsartan, Enalapril.

What is the status of PARADOR?

PARADOR is currently WITHDRAWN.

Last reviewed 2018-10-09 · How we verify

Prospective Comparison of an ARNI With an ACE Inhibitor on enDOthelial Function by Brachial Artery Reactivity (PARADOR)

NCT03119623 Phase 4 WITHDRAWN

PARADOR is multisite, randomized, double-blind, phase IV clinical trial to compare the effect of sacubitril/valsartan (Entresto™) to enalapril (Vasotec®) on blood vessel function in subjects with heart failure with reduced ejection fraction (HFREF).

Details

Lead sponsor	Brigham and Women's Hospital
Phase	Phase 4
Status	WITHDRAWN
Start date	2017-06-01
Completion	2019-08

Conditions

Heart Failure With Reduced Ejection Fraction

Interventions

sacubitril/valsartan
Enalapril

Primary outcomes

Flow Mediated Vasodilation — At study treatment completion (10 weeks)
To test the hypothesis that sacubitril/valsartan will improve endothelial function compared to enalapril, evidenced by increased flow mediated vasodilation (FMD) measured by brachial artery reactivity test (BART)